Known targets — ChEMBL curated mechanism
ABL1BMXBRAFBTKCHRNA4CHRNB2CSNK1EEGFRERBB2F10FLT1FLT3FLT4IGF1RINSRITKJAK3KDRKITOPRM1PARP1PARP2PDGFRBPIK3CDRAF1RETSLC18A2TECTXKdacAdacBdacCftsImrcAmrcBmrdArplArplBrplCrplDrplErplFrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmFrpmGrpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of None. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DPP4 | P27487 | 16/20 | 0.77 |
| ▸ | DPP8 | Q6V1X1 | 6/20 | 0.77 |
| ▸ | DPP9 | Q86TI2 | 4/20 | 0.77 |
| ▸ | PREP | P48147 | 3/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3390829 | 1.00 | DPP4 (0.77) | DPP4DPP8DPP9PREP | |
| SCHEMBL13000689 | 0.88 | DPP4 (1.00) | DPP4DPP8DPP9PREP | |
| SCHEMBL13000686 | 0.88 | DPP4 (1.00) | DPP4DPP8DPP9PREP | |
| SCHEMBL18098616 | 0.88 | DPP4 (1.00) | DPP4DPP8DPP9PREP | |
| SCHEMBL3759440 | 0.88 | DPP4 (1.00) | DPP4DPP8DPP9PREP | |
| SCHEMBL3395111 | 0.88 | DPP4 (1.00) | DPP4DPP8DPP9PREP | |
| Besigliptin SCHEMBL3397669 | 0.87 | DPP4 (0.58) | DPP4DPP8DPP9 | |
| Besigliptin SCHEMBL30786454 | 0.87 | DPP4 (0.58) | DPP4DPP8DPP9 | |
| Besigliptin SCHEMBL3757840 | 0.87 | DPP4 (0.58) | DPP4DPP8DPP9 | |
| SCHEMBL18098588 | 0.77 | DPP4 (0.78) | DPP4DPP8DPP9PREP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8415349-B2 | Dicycloazaalkane derivatives, preparation processes and medical uses thereof | Jiangsu Hansoh Pharmaceuticals Co., Ltd. (CN) | 2013-04-09 | — | — | US | disclosed |
| US-20130012705-A1 | DICYCLOAZAALKANE DERIVATIVES, PREPARATION PROCESSES AND MEDICAL USES THEREOF | JIANGSU HANSOH PHARMACEUTICAL CO., LTD. (CN) | 2013-01-10 | — | — | US | disclosed |
| US-8304411-B2 | Dicycloazaalkane derivates, preparation processes and medical uses thereof | JIANGSU HANSOH PHARMACEUTICAL CO., LTD. (CN) | 2012-11-06 | — | — | US | disclosed |
| US-20100311747-A1 | DICYCLOAZAALKANE DERIVATES, PREPARATION PROCESSES AND MEDICAL USES THEREOF | SHANGHAI HENGRUI PHARMACEUTICAL CO. LTD. (CN) | 2010-12-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130012705-A1 | DICYCLOAZAALKANE DERIVATIVES, PREPARATION PROCESSES AND MEDICAL USES THEREOF | DPP4, DPP8, DPP7 | DPP4 1/4885DPP8 2/4885DPP9 5/4885 |
| US-20100311747-A1 | DICYCLOAZAALKANE DERIVATES, PREPARATION PROCESSES AND MEDICAL USES THEREOF | DPP4, DPP8, DPP7 | DPP4 1/4885DPP8 2/4885DPP9 5/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.